Intrexon Corporation (XON) stock had a bullish inflow of $0.82 million worth of trades on uptick and an outflow of $0.56 million in downticks on Tuesday. The total uptick to downtick ratio stood at 1.46. The net money flow into the stock was $0.26 million. The money flow data, which is calculated as the dollar value of composite uptick minus the downtick trades indicated bullish. The block trades had a total money flow of $0.1 million. $0.1 million of block trade during Uptick was observed, which shows continued buying by the smart money on every weakness. However, Intrexon Corporation (XON) stock traded down $0.02 , and reached $26.21, a drop of -0.08% over the previous day. On a weekly basis, the stock is -1.91%, over the previous weeks close.
The company Insiders own 59.6% of Intrexon Corporation shares according to the proxy statements. Institutional Investors own 85.29% of Intrexon Corporation shares. In an insider trading activity, Kirk Randal J, CEO of Intrexon Corp, executed a transaction worth $3,714,334 on December 11, 2015. A total of 124,475 shares were purchased at an average price of $29.84. The Insider information was divulged by the Securities and Exchange Commission in a Form 4 filing. The information is based on open market trades at the market prices.Option exercises are not covered.
Shares of Intrexon Corporation rose by 2.86% in the last five trading days and 2.45% for the last 4 weeks. Intrexon Corporation has dropped 21.52% during the last 3-month period . Year-to-Date the stock performance stands at -14.13%.
Intrexon Corporation (NYSE:XON): On Tuesdays trading session , Opening price of the stock was $26.7 with an intraday high of $26.7299. The bears continued to sell at higher levels and eventually sold the stock down to an intraday low of $25.85. However, the stock managed to close at $25.89, a loss of 1.30% for the day. On the previous day, the stock had closed at $26.23. The total traded volume of the day was 1,107,396 shares.
Intrexon Corporation is engaged in the field of synthetic biology. The Company designs, builds and regulates gene programs, which are Deoxyribonucleic Acid (DNA) sequences that consist of genetic components. The Companys synthetic biology capabilities include the ability to control the amount, location and modification of biological molecules to control the function and output of living cells. The Companys technologies include UltraVector, RheoSwitch Therapeutic System, Cell Systems Informatics, Protein Engineering, AttSite Recombinases, LEAP (Laser Enabled Analysis and Processing), Antibody Discovery, Neurospora & Agaricus Platforms, Endometrial Regenerative Cells, ActoBiotics, Porcine Research Models and BeyondBio. The Company serves various markets, including health, food, energy, environment and consumer. The Company has five operating divisions: Human Therapeutics, Synthetic Immunology, Animal Sciences, Agricultural Biotech, and Industrial Products.